Status:
COMPLETED
Nimodipine for Treating Acute Massive Cerebral Infarction
Lead Sponsor:
Fengtian Hospital
Conditions:
Cerebral Infarction
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Massive cerebral infarction is an ischemic stroke caused by complete blockage of the internal carotid artery, middle cerebral artery, or their cortical branches. The widespread infarction, pathologica...
Detailed Description
In the clinic, physicians are reluctant to use thrombolysis, Defibrase and anticoagulation therapy because of the severity of symptoms, poor prognosis, risk of hemorrhage and high fatality rate that o...
Eligibility Criteria
Inclusion
- First onset at age ≤ 80 years, no other severe medical complications;
- Clear consciousness or mild disturbance of consciousness; paralysis of upper and lower extremities on one side with grade 0-3 muscle strength in paralyzed limbs;
- CT reveals early massive cerebral infarction (without cerebral hemorrhage or old infarction);
- Blood pressure within, or higher than, the normal range.
Exclusion
- Clinical manifestations are noticeably improved before treatment;
- Disorders of consciousness, manifesting as severe lethargy or coma;
- Mild neurological deficits, such as pure sensory disturbances, ataxia, dysarthria, and hemiparesis;
- Severe hypotension (systolic pressure \< 90 mmHg, diastolic pressure \< 60 mmHg);
- Heart rate \< 60 BPM; sinus bradycardia;
- Severe heart, brain or kidney dysfunction, or malignant tumor.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT02248233
Start Date
October 1 2014
End Date
September 1 2015
Last Update
May 1 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.